

---

**From:** Doug Boothe  
**Sent:** Wednesday, May 02, 2012 12:49 PM  
**To:** Michael Clarke  
**Subject:** RE: Suspicious Order Monitoring

Ok – my calendar is pretty open for tomorrow, so you make the call on timing.

Regarding resources, etc – there is certainly a process to review headcount, etc in light of the announced acquisition.

I think it depends on the depth of the request, and the implications as part of the expected ‘combined’ organization.

I would guess the bar will be ‘high’ to get incremental new approvals, but I know the justification is real – so we may need to juggle existing resources as an option.

DB

**Doug Boothe**  
*Chief Executive Officer, Actavis Inc.*



Actavis  
60 Columbia Rd. Bldg B t +1 973-889-6633 @ [DBOOTHE@actavis.com](mailto:DBOOTHE@actavis.com)  
Morristown , NJ 07960 United States f +1 973-993-4303 w [www.actavis.com](http://www.actavis.com)  
Internal VoIP number t 1256633

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

**From:** Michael Clarke  
**Sent:** Wednesday, May 02, 2012 2:53 PM  
**To:** Doug Boothe  
**Subject:** Suspicious Order Monitoring

Doug,

When you get a chance this week, I'd like to talk to you about resources for SOM. The working group is putting together a proposal that will include a resource request. The issues are number of additional FTEs and what department the resources should be located in (in order to avoid the perceived conflict with Sales/Market), but I'd like your thoughts on what is appropriate, given the current corporate situation.

Thanks.

Regards,

1



CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

PLAINTIFF TRIAL  
EXHIBIT  
**P-02392\_00001**

ALLERGAN MDI 02872103

P-02392\_00001

Michael

**Michael R. Clarke**

*Ethics & Compliance Officer, Americas*



Actavis

60 Columbia Rd. Bldg B † +1 973-889-6667 @ [MCLARKE@actavis.com](mailto:MCLARKE@actavis.com)

Morristown , NJ 07960 United States w [www.actavis.com](http://www.actavis.com)

Internal VoIP number † 125-6667

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.